Mats Wahlstrom Acquires 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom purchased 5,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was acquired at an average price of $4.55 per share, for a total transaction of $22,750.00. Following the completion of the transaction, the director now directly owns 15,727 shares of the company’s stock, valued at approximately $71,557.85. The trade was a 46.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom bought 2,040 shares of TriSalus Life Sciences stock. The stock was bought at an average cost of $4.16 per share, for a total transaction of $8,486.40.

TriSalus Life Sciences Stock Performance

TLSI opened at $4.23 on Tuesday. TriSalus Life Sciences, Inc. has a 1 year low of $3.61 and a 1 year high of $10.42. The company’s 50 day simple moving average is $4.25 and its 200 day simple moving average is $5.52. The stock has a market capitalization of $128.99 million, a PE ratio of -1.70 and a beta of 0.49.

Analyst Ratings Changes

TLSI has been the subject of a number of analyst reports. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Oppenheimer started coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Buy” and a consensus target price of $12.08.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently made changes to their positions in TLSI. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $66,000. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences during the third quarter worth about $92,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth about $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at about $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth about $240,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.